Sareum
Holdings PLC
("Sareum" or the
"Company")
Notice of Final Results for
the Year Ended 30 June 2024 and Investor
Presentation
Cambridge, UK, 23 October 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next-generation kinase inhibitors
for autoimmune disease and cancer, will announce its financial
results for the year ended 30 June 2024 on Tuesday, 29 October
2024.
The Company will also be holding a
live presentation to investors on Tuesday, 29 October 2024 at 14:30
GMT via the Investor Meet Company platform.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 28 Oct
2024, 09:00 GMT, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet SAREUM HOLDINGS PLC
via:
https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
Investors who already follow SAREUM
HOLDINGS PLC on the Investor Meet Company platform will
automatically be invited.
A copy of the presentation will be
made available on the Company's website following the
presentation.
- Ends -
For further
information, please contact:
|
Sareum Holdings plc
Stephen Parker, Executive
Chairman
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson Limited (Nominated
Adviser)
James Dance / James
Bellman
|
020 7409 3494
|
|
Hybridan LLP (Corporate
Broker)
Claire Noyce
|
020 3764 2341
|
|
ICR Healthcare (Financial
PR)
Jessica Hodgson / Davide Salvi /
Kumail Waljee
|
0203 709 5700
|
About
Sareum
Sareum Holdings (AIM:SAR) is a
clinical-stage biotechnology company
developing next generation kinase inhibitors for autoimmune disease
and cancer.
The Company is focused on developing
next generation small molecules which modify the activity of the
JAK kinase family and have best-in-class potential. Its lead
candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1.
SDC-1801 is a potential treatment for a range of autoimmune
diseases, including psoriasis, and has completed Phase 1 clinical
development.
Sareum is also developing SDC-1802,
a TYK2/JAK1 inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in
Cambridge, UK, and is listed on the AIM market of the London Stock
Exchange, trading under the ticker SAR. For further information,
please visit the Company's website at www.sareum.com